Millennium highlights updated survival results from the pivotal ADCETRIS ® (brentuximab vedotin) in patients with Hodgkins lymphoma trial in relapse or refractory
Millennium highlights pivotal with ADCETRIS ® (brentuximab vedotin) updated survival results from the test in patients with relapse or refractory Hodgkin’s lymphoma -ADCETRIS ® presents promising results to follow...
Read More
